dentifier":" anf-body- 31", "inlineTextStyles":[{"range":{"length":226,"start":0},"textsStyle":" anf-ts- i"},{"range™: {"length":226,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"In 2000, the agency issued a formal warning letter, saying that it had evidence the company was improperly marketing Thalomid for a variety of cancers as well as to promote a feeling of 4€egeneral well-beingdé€ in cancer patients.","type":"text"}, {"identifier":" anf-body- 32","inlineTextStyles":[{"range":{"length":175, "start":0},"textsStyle":"_ anf-ts- i"}, {"range™:{"length":175,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"a€ePerhaps more than for any other available drug, the need to provide and distribute thalidomide responsibly is essential to the public health, a4€ the agency wrote in the letter.","type"™:"text"}, {"additions"™: [{"URL":"https://www.sec.gov/Archives/edgar/data/8 16284/000100515001000229/0001005150-01- 000229.txt", "range": {"length":20,"start":286},"type™:"link"}],"identifier":" anf-body- 33","inlineTextStyles":[{"range":{"length":517, "start":0},"textsStyle":"_ anf-ts- 1"}, {"range"™:{"length":517,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"Over the next few years, however, Mr. Hugin and other top executives repeatedly referred to Thalomid 4€" and later Revlimid a4€" as the key to Celgenede™s financial future, even though it would not get formal approval to market the drugs to treat certain cancers until 2005 and 2006. In 2001, the company reported that 92 percent of Thalomidad€™s prescriptions were being written to treat cancer, and at an investor conference in 2004, Mr. Hugin said, Aa€eThalomid is important, because it is the financial engine that drives us.a4€","type":"text"}, {"identifier":" anf-body- 34","inlineTextStyles":[{"range":{"length":171,"start":0},"textsStyle":"_ anf-ts- i"}, {"range"™:{"length":171,"start":0},"textStyle":" anf-t